Laura Polacek
Harvard University
13 Papers
235 Citations
Laura Polacek is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson,Viktor A. Adalsteinsson,Gavin Ha,Gavin Ha,Samuel S. Freeman,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Denis Loginov,Denis Loginov,Dimitri Livitz,Daniel Rosebrock,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Joshua M. Francis,Cheng-Zhong Zhang,Cheng-Zhong Zhang,Ofir Cohen,Ofir Cohen,Coyin Oh,Huiming Ding,Paz Polak,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Rachel Leeson,Rachel M. Barry,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Nikhil Wagle,Gad Getz,Gad Getz,J. Christopher Love,J. Christopher Love,Matthew Meyerson +70 more
TL;DR: In this paper, a software called ichorCNA was proposed to quantitatively measure tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations.
•Journal Article
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Gavin Ha,Samuel S. Freeman,Atish D. Choudhury,Daniel G. Stover,Heather A. Parsons,Gregory Gydush,Sarah C. Reed,Denisse Rotem,Justin Rhoades,Dimitri Livitz,Daniel Rosebrock,Ignaty Leshchiner,Jaegil Kim,Chip Stewart,Mara Rosenberg,Joshua M. Francis,Cheng-Zhong Zhang,Ofir Cohen,Coyin Oh,Paz Polak,Max Lloyd,Sairah Mahmud,Karla Helvie,Margaret S. Merrill,Rebecca A. Santiago,Edward P. O’Connor,Seong Ho Jeong,Joseph F. Kramkowski,Zhenwei Zhang,Laura Polacek,Jens G. Lohr,Molly Schleicher,Emily Lipscomb,Andrea Saltzman,Nelly Oliver,Lori Marini,Adrienne G. Waks,Lauren C. Harshman,Sara M. Tolaney,Eliezer M. Van Allen,Eric P. Winer,Nan Lin,Mari Nakabayashi,Mary-Ellen Taplin,Cory M. Johannessen,Levi A. Garraway,Todd R. Golub,Jesse S. Boehm,Nikhil Wagle,Gad Getz,Matthew Meyerson,Viktor A. Adalsteinsson,Denis Loginov,Huiming Ding,Rachel Leeson,Rachel M. Barry,John C Love +56 more
TL;DR: The authors provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.
227
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
Joaquim Bellmunt,Aly-Khan A. Lalani,Aly-Khan A. Lalani,Sussana Jacobus,Stephanie A. Wankowicz,Laura Polacek,David Y. Takeda,Lauren C. Harshman,Nikhil Wagle,Nikhil Wagle,Irene Moreno,Kevin Lundgren,Dominick Bossé,Eliezer M. Van Allen,Eliezer M. Van Allen,Toni K. Choueiri,Jonathan E. Rosenberg +16 more
TL;DR: Combination therapy with E/P is safe in mUC and select patients with alterations in mTOR or FGFR pathways derive significant clinical benefit.
Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists
Leah E. Walsh,Laura Polacek,Katherine S. Panageas,Anne S. Reiner,Tobias Walbert,Alissa A. Thomas,Justin Buthorn,Allison Sigler,Holly G. Prigerson,Allison J. Applebaum,Eli L. Diamond +10 more
TL;DR: In this article , the authors examine communication processes and goals among patients, caregivers, and oncologists to elucidate drivers of prognostic understanding in the context of recurrent GBM.
9
Measuring a Patient's understanding of their prognosis: An exploratory analysis
Barry Rosenfeld,Leah E. Walsh,Danqi Zhu,Hei Ning Cham,Laura Polacek,Melissa Duva,Allison J. Applebaum +6 more
TL;DR: The initial development of a measure of prognostic understanding: the Prognostic Understanding Perceptions Scale (PUPS) for use in patients with advanced cancer is described.
5